Needham & Company raised estimates and its price target on Gilead Sciences (NASDAQ: GILD) from $62 to $70 following Q2 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Baird Downgrades Gilead Sciences (GILD) to NeutralJuly 26, 2013 10:03 AM Atlantic Equities Upgrades Gilead Sciences (GILD) to OverweightJuly 26, 2013 7:59 AM Gilead Sciences, Inc. (GILD) Reports In-Line Q2 EPSJuly 25, 2013 4:07 PM